Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

FDMTFDMT
23 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in 4D MOLECULAR THERAPEUTICS IN

CITADEL ADVISORS LLC holds 687,597 shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $9.1M as of 2026-Q2. The position was increased (+160.4% shares). FDMT represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$9.1M

Current Shares

687,597

Total Value Change

+$7M

Total Shares Change

+635,134

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
687,597
+160.4%
$9.1M0.0%$13.30
45
2026-Q1
Increased
264,096
+1227.8%
$2.5M0.0%$8.46
42
2025-Q4
New
19,889
-
$149,1680.0%$7.58
34
2025-Q3
Exited
0
-100.0%
$00.0%$8.35
0
2025-Q2
Decreased
192,239
-42.0%
$713,2070.0%$3.84
0
2025-Q1
Decreased
331,211
-45.3%
$1.1M0.0%$3.63
0
2024-Q4
Increased
605,092
+374.0%
$3.4M0.0%$5.30
43
2024-Q3
Increased
127,648
+74.4%
$1.4M0.0%$10.83
38
2024-Q2
Decreased
73,198
-17.0%
$1.5M0.0%$20.99
0
2024-Q1
Increased
88,229
+375.4%
$2.8M0.0%$31.86
42
2023-Q4
Decreased
18,558
-87.0%
$375,9850.0%$20.26
0
2023-Q3
Increased
143,220
+658.4%
$1.8M0.0%$12.73
42
2023-Q2
Increased
18,885
+287.6%
$341,2520.0%$17.73
38
2023-Q1
New
4,872
-
$83,7500.0%$16.75
33
2022-Q4
Exited
0
-100.0%
$00.0%$22.21
0
2022-Q3
Decreased
122,459
-45.6%
$984,0000.0%$8.22
0
2022-Q2
Increased
224,942
+363.5%
$1.6M0.0%$7.27
41
2022-Q1
Increased
48,533
+52.3%
$733,0000.0%$15.49
34
2021-Q4
Increased
31,877
+130.4%
$700,0000.0%$21.87
40
2021-Q3
Decreased
13,836
-49.3%
$373,0000.0%$27.92
0
2021-Q2
Increased
27,312
+39.2%
$658,0000.0%$23.50
32
2021-Q1
Decreased
19,616
-62.6%
$851,0000.0%$38.55
0
2020-Q4
New
52,463
-
$2.2M0.0%$41.64
36

Other major holders of FDMT: VIKING GLOBAL INVESTORS LP, RA CAPITAL MANAGEMENT, L.P., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used